Floatz logo

Tas-115

Alveolar Soft Part Sarcoma

Taiho Pharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Alveolar Soft Part Sarcoma cohort.

Asset / SponsorPhaseRating
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
Tivantinib
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Crizotinib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC

View all 22 →

Same molecule, other indications

Tas-115 is also rated in:

Advanced or Metastatic Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
39 / 100
View asset →
biliary tract cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →